Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by Future Fund LLC

Future Fund LLC boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 26.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,727 shares of the biopharmaceutical company’s stock after buying an additional 19,754 shares during the quarter. Future Fund LLC’s holdings in Catalyst Pharmaceuticals were worth $2,345,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Deerfield Management Company L.P. increased its stake in Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Catalyst Pharmaceuticals by 200.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after acquiring an additional 1,147,565 shares during the last quarter. Morgan Stanley lifted its position in shares of Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after acquiring an additional 1,089,775 shares in the last quarter. Glenmede Investment Management LP lifted its position in shares of Catalyst Pharmaceuticals by 781.8% in the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after acquiring an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Catalyst Pharmaceuticals by 30.6% in the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after acquiring an additional 554,200 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on CPRX. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Finally, Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.49 on Friday. The company’s 50 day simple moving average is $31.35 and its two-hundred day simple moving average is $27.01. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).